PerkinElmer Acquires Elcos AG

    Business Editors

    WELLESLEY, Mass.--(BUSINESS WIRE)--Feb. 10, 2005--

    Maker of High Performance LED Solutions for Biomedical
    Applications

    PerkinElmer Inc. (NYSE: PKI - News), a global leader in health sciences and industrial technologies, announced today the acquisition of Elcos AG, a leading European designer and manufacturer of custom LED (light emitting diode) solutions for biomedical and industrial applications.
    The transaction combines Elcos' visible LED technology platform and strong customer and application base with PerkinElmer's global sales, application and support organization, and will provide significantly greater growth opportunities for the Elcos technology.
    "Elcos has a successful track record of delivering high performance LED solutions to premier OEMs with the majority of their revenue in biomedical instrumentation," said John Roush, president, PerkinElmer Optoelectronics. "By bringing PerkinElmer and Elcos together we expand our offering of technology solutions for new and existing customers."
    Specialty LED solutions are well-suited for a variety of applications, including blood glucose monitoring and patient monitoring systems, as well as a number of industrial applications.
    "We have always respected PerkinElmer's unique ability to combine technology expertise, operational excellence and an intimate understanding of customers' needs in order to deliver customized total solutions. We strongly believe they are the right partner to take Elcos to the next level of success," said Joachim Sieg, founder and CEO of Elcos AG, who will stay on as a consultant after the acquisition is completed.
    Based in Pfaffenhofen, Germany, Elcos had 2004 revenues of $11.3M with over 60% coming from health sciences applications, including blood glucose monitoring and pulse oximetry. Except for the effects, if any, of acquisition accounting, the transaction is not expected to have any impact on the EPS of PerkinElmer in 2005. Consideration for the transaction was $15M cash and the potential for earn out payments based on the future performance of the business.

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results and plans concerning business development opportunities, are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
    PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

--30--DC/bo*

CONTACT: Dan Sutherby Investor Contact 781-431-4306 or Steve Marchant Brodeur Worldwide (617) 587-2864 smarchant@brodeur.com

KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL DEVICES BIOTECHNOLOGY MERGERS/ACQ SOURCE: PerkinElmer Inc.

Copyright Business Wire 2005